|
注册号: Registration number: |
ChiCTR-OOC-15005982 |
|
最近更新日期: Date of Last Refreshed on: |
2016-04-06 21:07:39 |
|
注册时间: Date of Registration: |
2015-02-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项对中国急性冠脉综合征伴血脂控制不佳的患者的观察性研究 |
|
Public title: |
An observational Study on the post-Acute coronary syndrome Patients with uncontrolled hyperlipidemia in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项对中国急性冠脉综合征伴血脂控制不佳的患者的观察性研究 |
|
Scientific title: |
An observational Study on the post-Acute coronary syndrome Patients with uncontrolled hyperlipidemia in China |
|
研究课题代号(代码): Study subject ID: |
ASAP |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘青 |
研究负责人: |
曹旭 |
|
Applicant: |
Qing LIU |
Study leader: |
Xu CAO |
|
申请注册联系人电话: Applicant telephone: |
+86 21 22266623 |
研究负责人电话:
Study leader's |
+86 10 65634983 |
|
申请注册联系人传真 : Applicant Fax: |
+86 21 60123538 |
研究负责人传真: Study leader's fax: |
+86 10 85215223 |
|
申请注册联系人电子邮件: Applicant E-mail: |
qing1.liu@sanofi.com |
研究负责人电子邮件: Study leader's E-mail: |
bonnie.cao@sanofi.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延安中路1228号静安嘉里中心办公楼3座19楼 |
研究负责人通讯地址: |
北京市朝阳区建国路108号海航实业大厦2层 |
|
Applicant address: |
19F Tower III, Kerry Centre 1228 Yan'an Road, Jing An District, Shanghai |
Study leader's address: |
2F, Haihang Building, No.108, Jian Guo Road, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
200040 |
研究负责人邮政编码: Study leader's postcode: |
100022 |
|
申请人所在单位: |
赛诺菲(中国)投资有限公司上海分公司 |
||
|
Applicant's institution: |
SANOFI (CHINA) INVESTMENT CO., LTD. SHANGHAI BRANCH |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2015[878] |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
北京大学第一医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Trials Ethnic Committee of Peking University First Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2015-02-05 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
北京大学第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University First Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区西什库大街8号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.8 Xishiku Street, Xicheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
赛诺菲(中国)投资有限公司上海分公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
SANOFI (CHINA) INVESTMENT CO., LTD. SHANGHAI BRANCH |
||||||||||||||||||||||
|
研究疾病: |
高脂血症 |
||||||||||||||||||||||
|
Target disease: |
Hyperlipidemia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
通过对近期内发生过急性冠脉综合征(ACS)事件、接受调脂治疗且未达治疗目标的中国患者进行观察,更好地了解患者的特征以及他汀类药物(阿托伐他汀、瑞舒伐他汀)强化治疗的使用情况。 探索患者降脂治疗目标未达成时不采用他汀类强化治疗的医学原因。 |
||||||||||||||||||||||
|
Objectives of Study: |
To better understand patient characteristics and the use of intensive statin (atorvastin, rosuvastin) treatments in Chinese patients who have recently experienced an acute coronary syndrome event and are under active lipid treatment and are not at therapeutic goal. To identify medical reasons that patient cannot adopt intensive statin treatment when patient’s therapeutic goal is not achieved. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 不能或不愿提供知情同意,包括但不限于认知或语言导致的理解力障碍 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Unable or unwilling to provide informed consent, including but not limited to cognitive or language barriers to comprehension; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2015-03-22 00:00:00至 To 2017-03-21 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2015-03-22 00:00:00 至 To 2017-03-21 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NA |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
NA |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
NA |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |